A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
Clinical trial NCT03952078 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03952078
- Sponsor
- Corvus Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-03
- Primary completion
- 2026-04-30
- Enrollment
- 151
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.